{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Biofrontera, Inc.
Biofrontera, Inc. Hits New 52-Week High of $1.52, Surges 57.45%
Biofrontera, Inc. has achieved a new 52-week high of USD 1.52, reflecting a substantial increase from its previous low of USD 0.55. Despite ongoing losses, the company maintains a market capitalization of USD 10 million and a price-to-book ratio of 0.91, indicating its unique financial position in the sector.
Is Biofrontera, Inc. technically bullish or bearish?
As of September 8, 2025, Biofrontera, Inc. shows a mildly bullish trend with positive MACD indicators, but caution is advised due to a bearish RSI and significant underperformance compared to the S&P 500.
Is Biofrontera, Inc. technically bullish or bearish?
As of June 10, 2025, Biofrontera, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and KST, while showing signs of consolidation without a clear trend.
What does Biofrontera, Inc. do?
Biofrontera, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $9 million and a net loss of $4 million as of March 2025. It has a market cap of $5.97 million and key metrics indicating significant financial challenges.
How big is Biofrontera, Inc.?
As of Jun 18, Biofrontera, Inc. has a market capitalization of 5.97 million, with net sales of 38.00 million and a net profit of -11.53 million over the last four quarters. Shareholder's funds are 4.43 million, and total assets are 22.10 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
